Losartan Potassium Active Pharmaceutical Ingredient (API) Market Report 2026

The losartan potassium active pharmaceutical ingredient (api) market size has grown strongly in recent years. It will grow from $1.85 billion in 2025 to $1.97 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rising prevalence of hypertension, expiration of branded drug patents, growth of generic pharmaceutical manufacturing, increased demand for cardiovascular drugs, expansion of global pharmaceutical supply chains.

The losartan potassium active pharmaceutical ingredient (api) market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growth in cardiovascular disease burden, increasing demand from emerging markets, advancements in api manufacturing technologies, rising focus on sustainable pharmaceutical production, expansion of chronic kidney disease treatment applications. Major trends in the forecast period include increasing demand for generic losartan formulations, growing adoption of continuous flow api manufacturing, rising focus on cost-efficient antihypertensive apis, expansion of losartan api use in combination therapies, increasing emphasis on regulatory-compliant api production.

The rising prevalence of hypertension is expected to drive the growth of the losartan potassium active pharmaceutical ingredient (API) market in the coming years. Hypertension is a condition characterized by persistently high blood pressure, which increases the risk of heart disease, stroke, and other serious health complications. The growing incidence of hypertension is linked to diets high in salt and processed foods, which contribute to fluid retention and increased strain on the heart. Losartan potassium helps manage hypertension by blocking angiotensin II, a hormone that constricts blood vessels, thereby relaxing and widening the vessels, lowering blood pressure, and reducing the heart’s workload. For example, in September 2025, according to the World Health Organization (WHO), a Geneva, Switzerland-based global health authority, approximately 1.4 billion adults aged 30-79 years had hypertension in 2024, compared with around 1.3 billion adults in 2022. Consequently, the increasing prevalence of hypertension is fueling the growth of the losartan potassium API market.

Major companies in the losartan potassium active pharmaceutical ingredient (API) market are focusing on developing innovative products and obtaining regulatory approvals, such as losartan potassium oral suspensions, to improve patient compliance and broaden therapeutic applications. Losartan potassium oral suspension is a liquid formulation of the medication designed for individuals who have difficulty swallowing tablets. For example, in March 2025, Scienture Holdings Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Arbli. Arbli is a ready-to-use liquid formulation indicated for hypertension, stroke risk reduction in hypertensive patients with left ventricular hypertrophy, and diabetic nephropathy in patients with type 2 diabetes. The product allows precise dosing without compounding and is available as a 165 mL peppermint-flavored suspension (10 mg/mL) with an 18-month shelf life at room temperature.

In April 2025, Scienture Holdings Inc., a US-based pharmaceutical company, partnered with Saptalis Pharmaceuticals LLC to manufacture Arbli (losartan potassium) Oral Suspension, 10 mg/mL, including warehousing and distribution arrangements. The collaboration aims to ensure market readiness for the first FDA-approved, ready-to-use oral liquid losartan, addressing unmet needs in hypertension treatment. Saptalis Pharmaceuticals LLC is a US-based pharmaceutical company specializing in the development and distribution of losartan potassium formulations.

Major companies operating in the losartan potassium active pharmaceutical ingredient (api) market are Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals Ltd, Lupin Ltd, Zydus Lifesciences Ltd, Alkem Laboratories Ltd, IPCA Laboratories Ltd, Alembic Pharmaceuticals Ltd, Granules India Limited, Vasudha Pharma Chem Ltd, IOL Chemicals and Pharmaceuticals Limited, Unichem Laboratories Ltd, Global Pharma Tek, Hetero Drugs Ltd, Manus Aktteva Biopharma LLP, Wellona Pharma, Atom pharma, Sinoway Industrial Co. Ltd, Cerata Pharmaceuticals LLP.

North America was the largest region in the losartan potassium API market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the losartan potassium active pharmaceutical ingredient (api) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the losartan potassium active pharmaceutical ingredient (api) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the losartan potassium api market by increasing costs of imported key starting materials, chemical intermediates, and manufacturing equipment. These effects are most pronounced in synthetic route production and bulk api exports, particularly across Asia-Pacific and Europe. Higher tariffs have pressured pricing for pharmaceutical companies and generic drug manufacturers. On the positive side, tariffs have encouraged localized api manufacturing and strengthened domestic pharmaceutical supply resilience.

The losartan potassium active pharmaceutical ingredient (api) market research report is one of a series of new reports that provides losartan potassium active pharmaceutical ingredient (api) market statistics, including losartan potassium active pharmaceutical ingredient (api) industry global market size, regional shares, competitors with a losartan potassium active pharmaceutical ingredient (api) market share, detailed losartan potassium active pharmaceutical ingredient (api) market segments, market trends and opportunities, and any further data you may need to thrive in the losartan potassium active pharmaceutical ingredient (api) industry. This losartan potassium active pharmaceutical ingredient (api) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Losartan potassium active pharmaceutical ingredient (API) refers to the pure, active compound used in the formulation of losartan-based medications for treating high blood pressure and protecting kidney function. It primarily helps manage hypertension, lowers the risk of heart attacks, and safeguards kidney function in diabetic patients.

The primary product types of losartan potassium API include tablets, capsules, and others. Tablets are the most common oral form, preferred for their ease of use, cost-effectiveness, and precise dosing in hypertension management. They are produced using various methods, including synthetic routes, biotechnological processes, and continuous flow production, and are distributed through channels such as online pharmacies, hospital pharmacies, retail pharmacies, and more. Applications include hypertension, heart failure, chronic kidney disease, and others, and they are used by hospitals, clinics, homecare settings, and pharmaceutical companies.

The losartan potassium active pharmaceutical ingredient (API) market consists of sales of bulk powder, granules, injectable concentrates, and pre-formulated intermediates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.